Ancowitz Bret, Shah Samir A
Division of Gastroenterology and Hepatology, Brown University Medical School, Providence, RI, USA.
Gastrointest Endosc Clin N Am. 2006 Oct;16(4):727-42. doi: 10.1016/j.giec.2006.08.016.
Gastroenterology practices looking to diversify their services may want to consider infusion therapies as an opportunity to provide a valuable service to patients and create an additional revenue stream. Although patients with gastrointestinal diseases may benefit from such infusions as crystalloid fluids for rehydration or iron for the treatment of inflammatory bowel disease is currently the only infusion therapy likely to be of economic benefit to the practice. The focus of this article is on the infusion of biologic agents, and it is assumed that such therapies will continue to play an important role in the management of inflammatory bowel disease for many years.
希望实现服务多元化的胃肠病诊疗机构不妨考虑将输液治疗作为一个契机，为患者提供有价值的服务并创造额外的收入来源。虽然胃肠道疾病患者可能会从诸如用于补液的晶体液或用于治疗炎症性肠病的铁剂等输液治疗中获益，但目前唯一可能给诊疗机构带来经济效益的输液治疗就是上述这些。本文的重点是生物制剂的输注，并且假定此类疗法在未来许多年里将继续在炎症性肠病的治疗中发挥重要作用。
